Broker upgrades CSL shares to 'buy' — could they hit $335?

Another upgrade for the biotech giant.

| More on:
A group of people in a corporate setting do a collective high five.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have caught a bid lately and lifted almost 6% in the past month, outpacing the broader S&P/ASX 200 Health Care Index (ASX: XHJ), which is up 3.7% in the same period.

In mid-morning trade on Thursday, shares in the biotech giant are swapping hands 1.1% higher at $298.02 apiece.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL4 Jul 20234 Jul 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24www.fool.com.au

Brokers are turning bullish on CSL shares, with the average analyst rating a buy, according to CommSec.

Citi has joined the club and revised its rating on the stock in a note on Thursday. Let's take a look.

CSL shares revised higher

Citi upgraded its recommendation on CSL shares to a buy in a note today, setting an ambitious price target of $335 per share, according to The Australian.

If the investment bank's 12-month projection is correct, a $1,000 investment in CSL shares today could be worth around $1,120 in a year. That's around 12% upside potential.

Citi's analysts might have been impressed by CSL's growth trajectory. Profits grew 17% year over year to $1.9 billion in H1 FY24, with earnings per share (EPS) of $4.18. Management is calling for $3 billion at the bottom line for the full year.

Meanwhile, Baker Young analysts project CSL's profits to compound by 21% annually in the coming three years.

Other expert opinions: The $500 club

This performance has attracted positive attention from several analysts. Macquarie also rates CSL shares a buy, with a similar price target of $330.

It highlights the strength of CSL's Behring division and sees a potential $500 per share valuation by 2027. It, too, sees double-digit earnings growth as a catalyst for this valuation.

Similarly, Sam Byrnes from ECP Asset Management forecasts that CSL shares could reach $500 by 2027.

Morgans also sees more upside, giving CSL rating and a more modest 12-month price target of $315. Again, earnings growth is driving this view.

Finally, Wilsons Advisory recently noted that CSL's earnings trajectory was stronger than the broader market, making its current valuation potentially attractive.

For reference, CSL trades on a forward price-to-earnings ratio (P/E) of around 38 times, so you decide that one.

Foolish takeout

Shares in the company have climbed by 7.7% over the past 12 months. With Citi's upgraded rating and other positive broker views, the experts certainly think CSL shares are well-positioned for further growth.

However, as always, consider your financial circumstances and risk tolerance before making any investment decisions.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man in a dark blue suit walks through an airport past floor-to-ceiling windows with a Qantas plane flying in the distance
Travel Shares

Up 16% this year, does Macquarie rate Corporate Travel Management shares a buy, hold or sell?

Does the travel stock have further to fly?

Read more »

group of friends checking facebook on their smartphones
Broker Notes

Macquarie tips 22% return for this ASX telco stock

This telco could be undervalued at current levels according to the broker.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.
Broker Notes

Passive income: What's CBA's dividend outlook according to Macquarie?

Is CBA still a top passive income stock?

Read more »

A smiling woman looks at her phone as she walks with her suitcase inside an airport.
Broker Notes

Down 41% in a year, why Macquarie thinks Flight Centre shares are set to rebound

Is Flight Centre about to take off?

Read more »

A group of miners in hard hats sitting in a mine chatting on a break as ASX coal shares perform well today
Broker Notes

Does Macquarie rate Liontown Resources shares a buy, hold or sell?

Let’s find out what the broker had to say.

Read more »

Machinery at a mine site.
Broker Notes

Up 48% this year, does Macquarie think Lynas Rare Earths has further to run?

Changing market dynamics.

Read more »

A couple cheers as they sit on their lounge looking at their laptop and reading about the rising Redbubble share price
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »